Investor directory

Arvinas

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, focused on developing therapies that target and degrade disease-causing proteins. The company employs its proprietary Proteolysis-Targeting Chimera (PROTAC) technology, which harnesses the body's own cellular mechanisms to eliminate harmful proteins. Arvinas' lead product candidates include ARV-110, currently in phase I clinical trials for treating metastatic castration-resistant prostate cancer by targeting the androgen receptor, and ARV-471, aimed at treating metastatic ER-positive/HER2-negative breast cancer through estrogen receptor degradation. Additionally, the company is exploring other PROTACs and therapeutic options for neurodegenerative diseases. Founded in 2015, Arvinas has established collaborations with major pharmaceutical companies such as Pfizer, Genentech, and Bayer to advance its innovative drug development efforts.
http://www.arvinas.com
https://crunchbase.com/organization/arvinas
https://facebook.com/100578376985397
https://linkedin.com/company/arvinas
https://twitter.com/arvinasinc
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=243040896

Randy Teel

Interim CFO and Treasurer

1 past transactions

Oerth Bio

Corporate Round in 2020
Oerth Bio LLC is a biotechnology company focused on developing innovative solutions for crop protection through the use of targeted protein degraders. Founded in 2019 and based in Durham, North Carolina, the company utilizes PROTAC (proteolysis targeting chimeras) technology to create effective agricultural applications. This approach allows Oerth Bio to enhance crop yields while reducing reliance on harmful pesticides, ultimately promoting sustainable agricultural practices. By targeting protein degraders, the company aims to produce cleaner and healthier crops, contributing to the overall improvement of agricultural efficiency and safety.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.